Research terms, explained.

An unfavorable health event recorded during a study. Its occurrence alone does not establish that the studied intervention caused it.

In your reading: A trial may report nausea in both intervention and comparison groups; read their frequencies and follow-up.

Sources: CONSORT: trial reporting

A substance that binds to a receptor and activates a response through it. The response depends on the receptor and the studied system.

In your reading: A receptor assay can show agonist activity without answering whether an intervention benefits people.

Sources: IUPHAR: receptors

A molecular building block of peptides and proteins. Each amino acid has a side group that helps distinguish its chemical properties.

In your reading: The letters in GHK stand for glycine, histidine and lysine, in that order.

Sources: NCBI: chemical components

A molecule related to another molecule but with defined chemical differences. Similarity does not make their properties or evidence interchangeable.

In your reading: A modified GHRH analogue needs its own identity and studies, even when its name refers to GHRH.

Sources: Jetté et al., 2005

A substance that reduces a receptor-mediated response to an agonist without activating that receptor in the same way.

In your reading: Blocking a response can help test a receptor's role; it does not settle every step of the mechanism.

Sources: IUPHAR: receptors

Area under a concentration–time curve. In pharmacokinetics, it summarizes measured exposure over the stated time interval.

In your reading: An AUC value needs its sampling interval and units; it is not a direct measure of benefit.

Sources: FDA: AUC and Cmax terminology · NCBI: pharmacokinetic principles

The fraction of an administered substance that reaches the systemic circulation unchanged. It depends on the exact formulation and route.

In your reading: Findings for one oral formulation do not establish the exposure from another product with the same peptide name.

Sources: NCBI: pharmacokinetics

A measured characteristic used as an indicator of a biological process, disease process, or response to an exposure or intervention.

In your reading: A change in a blood marker can answer a biological question without measuring how a person feels or functions.

Sources: FDA: endpoints and biomarkers

A mixture of materials. A blend's name does not specify one peptide sequence, and studies of individual ingredients do not establish effects of the mixture.

In your reading: Read KLOW's ingredient identities separately from claims about the named blend.

Sources: IUPAC: peptides · CONSORT: trial reporting

Keeping specified people unaware of assigned interventions to reduce bias. A report should say who was blinded and how.

In your reading: The label 'double-blind' is more useful when the paper identifies which participants and assessors lacked that information.

Sources: FDA / ICH: trial statistics

A pharmacokinetic measure of removal, expressed as the volume of plasma or blood effectively cleared of a substance per unit time.

In your reading: Clearance can help explain exposure differences between studied populations. It is different from half-life.

Sources: NCBI: pharmacokinetic principles

Research in people that prospectively assigns an intervention to evaluate its effects. The participants, design and measured outcomes define what it can answer.

In your reading: An early trial in healthy adults and a longer trial in a disease population answer different questions.

Sources: NIH: clinical trials

The maximum observed concentration in a concentration–time profile. Its meaning depends on the sample type, sampling times and studied conditions.

In your reading: A similar peak concentration does not guarantee a similar total exposure; AUC describes another part of the profile.

Sources: FDA: AUC and Cmax terminology

A range showing uncertainty around an estimate under a statistical method. A 95% method captures the true value in 95% of repeated applications, if its assumptions hold.

In your reading: A wide interval can leave both meaningful benefit and little effect compatible with the data.

Sources: FDA / ICH: trial statistics

A molecule's three-dimensional arrangement. A peptide can adopt different conformations; sequence alone is not a picture of its shape in every setting.

In your reading: A chain's arrangement can affect how it meets a receptor or binds another molecule.

Sources: NCBI: protein shape

A chemical entity in which copper is coordinated by binding groups of other molecules. The peptide and its copper complex have distinct identities.

In your reading: GHK and GHK-Cu are related names, but the copper suffix belongs to the material being studied.

Sources: Freedman et al., 1982

In 'CJC-1295 with DAC,' the label identifies an albumin-binding extension attached to the analogue. This distinguishes it from materials described without that extension.

In your reading: A CJC-1295-with-DAC report cannot simply be reassigned to Modified GRF(1–29). Check the full material name.

Sources: Jetté et al., 2005

A defined outcome used to address a study question. Its measurement and timing matter; a primary endpoint is the main outcome specified for the trial.

In your reading: Body-weight change at a stated week is different from an assay of receptor activity.

Sources: FDA: endpoints and biomarkers · CONSORT: trial reporting

A portion of a longer amino-acid chain. A fragment has its own sequence and cannot inherit all findings about the full chain.

In your reading: Distinguish a thymosin β4 fragment name from studies of full-length thymosin β4.

Sources: NCBI: primary structure

Growth hormone, a protein hormone released by the pituitary. It participates in growth and metabolism, with many actions mediated through IGF-1.

In your reading: A rise in measured GH describes a hormone response; it does not by itself establish a clinical benefit.

Sources: NCBI: growth hormone physiology

Growth hormone-releasing hormone, a signal from the hypothalamus that stimulates pituitary cells to release growth hormone.

In your reading: GHRH analogues target this signaling pathway; they are distinct from growth hormone itself.

Sources: NCBI: growth hormone physiology · Jetté et al., 2005

Glucose-dependent insulinotropic polypeptide, an incretin hormone. GIPR names its receptor; a GIP-receptor agonist activates that receptor.

In your reading: The tirzepatide profile discusses GIP and GLP-1 receptor activity as two separate targets.

Sources: Retatrutide receptor study, 2024

Glucagon-like peptide-1, an incretin hormone involved in nutrient-related signaling. GLP-1R is its receptor; the hormone, receptor and receptor agonists are distinct things.

In your reading: Semaglutide is a GLP-1 receptor agonist; 'GLP-1' alone does not identify the studied product.

Sources: Retatrutide receptor study, 2024

A peptide hormone involved in metabolic regulation. GCGR is the glucagon receptor, a separate target from GLP-1R and GIPR.

In your reading: Retatrutide's 'triple agonist' description refers to activity at three named receptors, including GCGR.

Sources: Retatrutide receptor study, 2024

The time for a measured amount or concentration to fall by half during a specified phase. It describes decline, not the duration of every biological effect.

In your reading: A reported half-life needs the material, population and measurement context. It does not supply a use schedule.

Sources: NCBI: pharmacokinetics

Glycated hemoglobin: a blood measurement that reflects average glucose over roughly the past three months. It is commonly reported in diabetes studies.

In your reading: An HbA1c change and a body-weight change are separate outcomes, even when the same trial reports both.

Sources: NIDDK: the A1C test

Insulin-like growth factor-1, a signaling protein involved in growth and metabolism. It mediates many, but not all, actions of growth hormone.

In your reading: GH and IGF-1 measurements describe related parts of a pathway; neither is a substitute for every clinical outcome.

Sources: NCBI: growth hormone physiology

The tendency of a material to provoke an immune response. For therapeutic proteins or peptides, researchers may assess antibodies and their possible effects.

In your reading: Detecting antibodies and showing that those antibodies alter an effect are different findings.

Sources: FDA: immunogenicity

Research outside an intact living organism, such as a cell assay. The particular cells, material and measured response define the model.

In your reading: A cell response can support a mechanism question while leaving exposure and outcomes in people unanswered.

Sources: NCBI: cell communication · ARRIVE: animal-study reporting

Research in a living organism. The term does not specify whether that organism is a person, mouse, rat or another species.

In your reading: An in vivo rat wound study is still an animal study, not a human clinical trial.

Sources: ARRIVE: animal-study reporting

A molecule that binds to another molecule, such as a receptor. Binding and receptor activation are related but separate observations.

In your reading: Calling a molecule a receptor ligand does not tell you whether it activates, blocks or otherwise changes the receptor's response.

Sources: IUPHAR: receptors

The mass of a constituent divided by the total solution volume. Units such as mg/mL describe mass per volume.

In your reading: A mass-per-volume value differs from mol/L, which describes the amount of substance per volume.

Sources: IUPAC: mass concentration

A process proposed or observed to explain an effect. A plausible process and a demonstrated clinical outcome require different evidence.

In your reading: Receptor activation can be part of a mechanism, while a trial tests an outcome in a defined population.

Sources: NCBI: cell communication · IUPHAR: pharmacodynamics

The amount of a constituent, in moles, divided by the total solution volume. M means mol/L; mM and µM are smaller units of the same quantity.

In your reading: Converting a mass concentration to molar concentration requires the molar mass of the exact chemical form.

Sources: IUPAC: amount concentration

A molecule made of amino-acid units joined by peptide bonds. Its sequence and any chemical changes help define the material.

In your reading: A shared peptide label does not make a full chain, a fragment and a commercial blend the same material.

Sources: IUPAC: peptides

The amide linkage connecting amino-acid units in a peptide chain. These links form the backbone, with the amino acids' side groups extending from it.

In your reading: The links hold a chain together; the order of its amino-acid units is the sequence.

Sources: NCBI: primary structure

The study of what a substance does to a biological system, including the relationship between exposure and response.

In your reading: Receptor-response measurements describe pharmacodynamics; concentration over time describes pharmacokinetics.

Sources: IUPHAR: pharmacodynamics

The study of how a substance's concentration changes with time through absorption, distribution, metabolism and removal.

In your reading: A laboratory concentration and a measured concentration in people describe different exposure settings.

Sources: NCBI: pharmacokinetics

A comparison intervention designed to resemble the tested intervention while lacking its active component. It helps interpret changes that also occur without that component.

In your reading: Compare the intervention and placebo groups' outcomes, rather than relying on change in the intervention group alone.

Sources: NIH: clinical trials

A probability calculated under a specified statistical model for a result at least as extreme as the observed one. It does not give the probability that a hypothesis is true.

In your reading: A small p-value does not establish a large or useful effect. Read the effect estimate, uncertainty and study design too.

Sources: ASA: interpreting p-values

A trial that assigns participants by chance to intervention and comparison groups. Randomization reduces allocation bias; it does not remove every study limitation.

In your reading: Still inspect who participated, what was compared, missing data, follow-up and measured outcomes.

Sources: FDA / ICH: trial statistics · CONSORT: trial reporting

A molecule, often a protein, that recognizes a signal and can participate in a biological response. Receptor expression and context affect that response.

In your reading: GLP-1R, GIPR and GCGR are different receptor targets, even when one molecule acts at all three.

Sources: NCBI: cell communication · Retatrutide receptor study, 2024

The order of amino-acid units in a chain, conventionally written from the amino end to the carboxyl end. Different orders identify different chains.

In your reading: GHK records an order, not just a list of three amino-acid ingredients.

Sources: NCBI: primary structure

An endpoint used in place of directly measuring how a person feels, functions or survives. Evidence is needed to support what it predicts in a specific context.

In your reading: A biomarker change is not automatically a validated substitute for the clinical outcome you care about.

Sources: FDA: endpoints and biomarkers